TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06496594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol prophylactic powders
Description: erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scaler with peek inserts
Description: ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
Study: NCT05884398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation Therapy (ADT)
Description: The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation Therapy (ADT)
Description: The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Study: NCT05386680

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OAV101
Description: Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
Study: NCT05679154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-focused Implementation
Description: CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation
Description: CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
Study: NCT05916950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thor laser atherectomy
Description: Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
Study: NCT06266364

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active VNS stimulation
Description: The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VNS stimulation
Description: The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
Study: NCT05133050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
Study: NCT05275439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT06352359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-841
Description: ONC-841 (anti-SIGLEC10) is a humanized antibody that binds to human sialic acid-binding Ig-like lectin 10 and has a human immunoglobulin G4 (IgG4) Fc domain.
Study: NCT05688280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% IP-001 for Injection
Description: 4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% IP-001 for Injection
Description: 4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% IP-001 for Injection
Description: 4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
Study: NCT05814549

Intervention type: DIAGNOSTIC_TEST
Intervention: NavDx
Description: Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints~o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase.
Study: NCT05088915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Intervention for PTSD (PCIP)
Description: This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
Study: NCT06029127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered intravenously at protocol defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered intravenously at protocol defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered intravenously at protocol defined dose

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Ramucirumab
Description: 10 mg/kg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered orally at protocol defined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered orally at protocol defined dose
Study: NCT04109027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainStrong-GSR
Description: Goal-directed State Regulation Training (GSR)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BrainStrong-OPT
Description: Optimization of Brain Functioning (OPT)
Study: NCT06483061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol will be injected to enhance MRI images
Study: NCT05456880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEAM-101
Description: Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
Study: NCT04965090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
Study: NCT04454684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-directive therapy
Description: Non-directive therapy will be conducted during Experimental Sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-directive therapy
Description: Non-directive therapy will be conducted during Experimental Sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy will be conducted during Preparatory Sessions and Integrative Sessions.
Study: NCT04506151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-Opt
Description: 12-week behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: Healthy Living
Study: NCT06137183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.
Study: NCT06140524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion
Study: NCT04849221

Intervention type: OTHER
Intervention: Tympanometry measurement in both ears
Description: Measurement once or twice a day and at every change of more than 10 mmHg in ICP, over the entire period of time that ICP is measured by a probe or DVE

Intervention type: OTHER
Intervention: Collection of clinical and paraclinical data
Description: Patient: gender, weight/height, age, etiology of ICP entry, reason for ICP monitoring, presence of external (otoscopy), middle (otoscopy + CT) or internal (CT) ear abnormality, presence of inclusion and non-inclusion criteria, measurement of patient tilt.~healthy subjects: gender, weight/height, age, presence of abnormality of the external (otoscopy), middle (otoscopy) or internal ear (questioning), presence of inclusion and non-inclusion criteria...

Intervention type: OTHER
Intervention: Collection of clinical and paraclinical data
Description: Patient: gender, weight/height, age, etiology of ICP entry, reason for ICP monitoring, presence of external (otoscopy), middle (otoscopy + CT) or internal (CT) ear abnormality, presence of inclusion and non-inclusion criteria, measurement of patient tilt.~healthy subjects: gender, weight/height, age, presence of abnormality of the external (otoscopy), middle (otoscopy) or internal ear (questioning), presence of inclusion and non-inclusion criteria...

Intervention type: OTHER
Intervention: Intracranial pressure reading (ICP)
Description: a single measure

Intervention type: OTHER
Intervention: Intracranial pressure reading (ICP)
Description: a single measure
Study: NCT05556915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided AVF cannulation method
Description: For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional AVF cannulation method
Description: The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
Study: NCT06391684

Intervention type: BEHAVIORAL
Intervention: Social/non social; predictable vs unpredictable
Description: Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)

Intervention type: BEHAVIORAL
Intervention: Social/non social; predictable vs unpredictable
Description: Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)
Study: NCT05509725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Description: Participants will be asked to take 2 doses daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take 2 doses daily
Study: NCT05762848

Intervention type: DEVICE
Intervention: Mobile Phone Head Circumference App
Description: Measurement of Head circumference of Babies/Infants with a mobile phone application.

Intervention type: DEVICE
Intervention: Mobile Phone Head Circumference App
Description: Measurement of Head circumference of Babies/Infants with a mobile phone application.
Study: NCT06340074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELM
Description: HELM is a 9-month, data-driven organizational and leadership implementation strategy that entails eight core components: 1) Assessment and Feedback. 2) Initial Training. 3) Leadership Development Plan. 4) Individual Coaching. 5) Group Coaching. 6) Organizational Strategy Development. 7) Professional Learning Collaboratives. 8) Graduation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Implementation Attention Control (IAC)
Description: Schools assigned to the IAC condition received an online, self-paced, independent studies program broadly focused on leadership and management. The program did not specifically discuss implementation leadership or climate. The program included four content modules hosted on a web-based learning portal: 1) Motivating and Engaging Employees, 2) Authentic Leadership, 3) Managing Diverse Teams, and 4) Fostering an Idea Culture. Each module consisted of one content-specific 60-minute webinar.
Study: NCT05673408

Intervention type: DEVICE
Intervention: Philips IntelliVue X3 Patient Monitor
Description: All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.

Intervention type: DEVICE
Intervention: Philips IntelliVue X3 Patient Monitor
Description: All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.

Intervention type: DEVICE
Intervention: Philips IntelliVue X3 Patient Monitor
Description: All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.
Study: NCT05664932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
Description: Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZF2001
Description: Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
Study: NCT04332211

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 MG
Description: administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
Study: NCT05034848

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Assessment of BMD by DXA and HRpQCT
Description: * DXA : BMD assessment at the left hip, rachis and both legs~* HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs~* Biological samples
Study: NCT06614049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications
Description: Receive personalised feedback and educational content curated by local clinicians and pharmacists through the CADENCE D-PHA app coupled with six sessions of human coaching on top of usual clinical care for lipid management over 6 months
Study: NCT04704700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repair of a cuff tear
Description: Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repair of a cuff tear
Description: Group (Control): standard Arthroscopic repair of the cuff rotator
Study: NCT06624579

Intervention type: PROCEDURE
Group type: OTHER
Intervention: confocal endomicroscopy
Description: The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.
Study: NCT06682286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIV mask A
Description: Bridge free face mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIV mask A
Description: Bridge free face mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIV mask B
Description: Full face mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIV mask B
Description: Full face mask
Study: NCT06719037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endo-Surgi Plus endoscopic surgery
Description: Endo-Surgi Plus endoscopic surgery, as a new type of percutaneous endoscopic lumbar discectomy (PELD), features a larger working channel and represents an optimized single-channel endoscopic technique. However, it still has the limitations inherent in single-channel endoscopy.
Study: NCT04454684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy will be conducted during Preparatory Sessions and Integrative Sessions.
Study: NCT06719037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral biportal endoscopic surgery
Description: Unilateral biportal endoscopic discectomy (UBE) is characterized by its separate endoscopic and working channels, and the ability to use traditional open instruments, making it a convenient and versatile technique. It is a commonly used spinal endoscopic surgery in clinical practice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Microdiscectomy (MD) is a mature minimally invasive technique that uses a microscope to treat lumbar spinal stenosis. As early as 1999, prospective randomized controlled studies confirmed that it has equally excellent clinical efficacy compared to open surgery, with less surgical trauma. It is currently the classic minimally invasive surgical approach for treating lumbar spinal stenosis.
Study: NCT06737185

Intervention type: OTHER
Group type: OTHER
Intervention: EAFS4T: modification with evolutionary algorithm of tonotopic-based fitting
Description: Comparison of FS4T and EAFS4T
Study: NCT06764407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient preferential music
Description: Patients will listen to their preferred music through the headphones before surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Music
Description: Patients will not listen to music.